Analysts Set Unicycive Therapeutics, Inc. (NASDAQ:UNCY) PT at $34.33

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) has earned an average rating of “Moderate Buy” from the five ratings firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $34.3333.

Several analysts have recently issued reports on UNCY shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Unicycive Therapeutics in a research report on Monday, December 29th. Westpark Capital started coverage on shares of Unicycive Therapeutics in a research note on Thursday, February 19th. They issued a “buy” rating on the stock. Finally, Guggenheim reiterated a “buy” rating on shares of Unicycive Therapeutics in a research note on Tuesday, December 30th.

Unicycive Therapeutics Stock Performance

NASDAQ:UNCY opened at $6.76 on Monday. The company has a fifty day moving average of $6.60 and a two-hundred day moving average of $5.62. The stock has a market capitalization of $145.27 million, a PE ratio of -1.71 and a beta of 1.82. Unicycive Therapeutics has a fifty-two week low of $3.71 and a fifty-two week high of $11.00.

Institutional Trading of Unicycive Therapeutics

Large investors have recently made changes to their positions in the company. Lazard Asset Management LLC acquired a new position in Unicycive Therapeutics in the 2nd quarter valued at $55,000. JPMorgan Chase & Co. boosted its stake in Unicycive Therapeutics by 11,698.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock worth $104,000 after purchasing an additional 21,525 shares during the last quarter. Quadrature Capital Ltd purchased a new stake in shares of Unicycive Therapeutics during the fourth quarter worth $226,000. Citadel Advisors LLC purchased a new stake in shares of Unicycive Therapeutics during the third quarter worth $182,000. Finally, State Street Corp raised its position in shares of Unicycive Therapeutics by 19.0% in the fourth quarter. State Street Corp now owns 65,227 shares of the company’s stock valued at $376,000 after buying an additional 10,400 shares during the last quarter. 40.42% of the stock is currently owned by hedge funds and other institutional investors.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.